These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31346408)

  • 1. Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study.
    Ulambayar B; Yang EM; Cha HY; Shin YS; Park HS; Ye YM
    Clin Transl Allergy; 2019; 9():33. PubMed ID: 31346408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New transcriptome and clinical findings of platelet-activating factor in chronic spontaneous urticaria: Pathogenic and treatment relevance.
    Andrades E; Clarós M; Torres JV; Nonell L; González M; Curto-Barredo L; Rozas-Muñoz E; Gimeno R; Barranco C; Pujol RM; Izquierdo I; Giménez-Arnau AM
    Biofactors; 2022 Nov; 48(6):1284-1294. PubMed ID: 35927787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-heat shock protein 10 IgG in chronic spontaneous urticaria: Relation with miRNA-101-5p and platelet-activating factor.
    Choi BY; Yang EM; Jung HW; Shin MK; Jo J; Cha HY; Park HS; Kang HC; Ye YM
    Allergy; 2023 Dec; 78(12):3166-3177. PubMed ID: 37415527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Levels of Vascular Endothelial Growth Factor, Platelet Activating Factor and Eosinophil-Derived Neurotoxin in Chronic Spontaneous Urticaria-A Pilot Study in Adult Patients.
    Gomułka K; Mędrala W
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Associated With Refractoriness to an Up to Fourfold Dosage of Antihistamines in Isolated Chronic Spontaneous Urticaria.
    Wongjirattikarn R; Chaowattanapanit S; Foocharoen C; Sawanyawisuth K; Choonhakarn C; Julanon N; Utchariyaprasit E
    J Cutan Med Surg; 2022; 26(6):593-599. PubMed ID: 36172833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
    Magen E; Waitman DA; Kahan NR
    Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased serum soluble vascular endothelial cadherin levels in patients with chronic spontaneous urticaria.
    Chen T; Guo ZP; Wang WJ; Fu LX; Sun QM; Zhou PM
    Ann Allergy Asthma Immunol; 2017 Jun; 118(6):704-709. PubMed ID: 28583263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased serum free IgE levels in patients with chronic spontaneous urticaria (CSU).
    Jang JH; Yang EM; Lee Y; Ye YM; Moon J; Ryu MS; Park HS
    World Allergy Organ J; 2022 Feb; 15(2):100629. PubMed ID: 35280503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy.
    Perelman B; Adil A; Vadas P
    Allergy Asthma Clin Immunol; 2014; 10(1):20. PubMed ID: 24808915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated MRGPRX2 Levels Related to Disease Severity in Patients With Chronic Spontaneous Urticaria.
    Cao TBT; Cha HY; Yang EM; Ye YM
    Allergy Asthma Immunol Res; 2021 May; 13(3):498-506. PubMed ID: 33733642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
    Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
    Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilastine in Refractory Chronic Spontaneous Urticaria: Disease Control and Cytokine Modulation in an Open-label Prospective Study.
    De A; Singh S; Chakraborty D; Sarda A; Godse K
    Indian J Dermatol; 2024; 69(2):132-136. PubMed ID: 38841225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The socio-economic burden of H1-antihistamine-refractory chronic spontaneous urticaria in Germany.
    Augustin M; Beier D; Branner J; Häckl D; Hampel R; Kramps T; Kurzen H; Lintener H; Melzer N; Müller M; Staubach P; Schwichtenberg U; Termeer C; Zink A; Nathan P; Maurer M
    J Eur Acad Dermatol Venereol; 2024 May; ():. PubMed ID: 38733261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis.
    Vadas P; Gold M; Perelman B; Liss GM; Lack G; Blyth T; Simons FE; Simons KJ; Cass D; Yeung J
    N Engl J Med; 2008 Jan; 358(1):28-35. PubMed ID: 18172172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of H1- and H2-antihistamines on platelet-activating factor and bradykinin-induced inflammatory responses in human skin.
    Sansom JE; Brooks J; Burton JL; Archer CB
    Clin Exp Dermatol; 1996 Jan; 21(1):33-7. PubMed ID: 8689766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.
    Potter P; Mitha E; Barkai L; Mezei G; Santamaría E; Izquierdo I; Maurer M
    Pediatr Allergy Immunol; 2016 Feb; 27(1):55-61. PubMed ID: 26267219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment.
    Kolkhir P; Church MK; Altrichter S; Skov PS; Hawro T; Frischbutter S; Metz M; Maurer M
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):318-325.e5. PubMed ID: 31472293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.
    Tselepis AD; Goudevenos JA; Tambaki AP; Michalis L; Stroumbis CS; Tsoukatos DC; Elisaf M; Sideris DA
    Cardiovasc Res; 1999 Jul; 43(1):183-91. PubMed ID: 10536703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of maternal plasma platelet activating factor acetylhydrolase activity and mRNA expression in pre-eclampsia: a case control study.
    Gupta P; Agarwal R; Bhaskaran S; Garg S; Mehndiratta M; Radhakrishnan G; Singh A; Agarwal R; Narang D
    J Obstet Gynaecol; 2021 Jul; 41(5):726-732. PubMed ID: 33073639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.